LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma
Condition(s):Advanced Soft-tissue SarcomaLast Updated:June 9, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Advanced Soft-tissue SarcomaLast Updated:June 9, 2023Recruiting
Condition(s):Malignant AscitesLast Updated:January 11, 2024Recruiting
Condition(s):Cancer of PancreasLast Updated:February 9, 2021Unknown status
Condition(s):Idiopathic Pulmonary FibrosisLast Updated:January 20, 2023Recruiting
Condition(s):Pancreatic CancerLast Updated:March 26, 2019Terminated
Condition(s):Stroke, Acute Ischemic; Endovascular Procedures; Large Vessel OcclusionLast Updated:December 1, 2023Recruiting
Condition(s):HIV Infections; DyslipidemiasLast Updated:February 8, 2023Terminated
Condition(s):Venous Thromboembolism; Deep Vein Thrombosis; Trauma, MultipleLast Updated:November 29, 2018Unknown status
Condition(s):Rectal CancerLast Updated:November 8, 2023Active, not recruiting
Condition(s):ObesityLast Updated:October 27, 2017Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.